Jefferies on Annexon Biosciences (ANNX): APLS deal shows 'big pharma interested in complement space'
Tweet Send to a Friend
Jefferies analyst Andrew Tsai reiterated a Buy rating and $10.00 price target on Annexon Biosciences (NASDAQ: ANNX)The analyst commented, "APLS ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
